13F-HR filed by Octagon Capital Advisors LP
Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2026-03-31, filed 2026-05-15, with 29 holding rows worth $903,605,540.
- Accession
- 0001839435-26-000003
- Filer
- CIK 1839435
- Filed
- 2026-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2026
A holdings report, 29 entries on the cover page, a total value of $903,605,540 stated on the cover page (in dollars after the unit check, H1), rows summing to $903,605,540 with VALUE read as dollars as filed, 13F file number 028-20958. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 1,946,667 | $163,364,295 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 2,350,000 | $90,451,500 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 677,000 | $75,383,950 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 2,830,700 | $62,360,321 | dollars as filed | |
| DEFINIUM THERAPEUTICS INC | 24477V105 | COM SHS | 2,440,000 | $46,116,000 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 1,971,054 | $45,472,216 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 8,859,911 | $39,603,802 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 425,000 | $35,398,250 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 338,900 | $31,307,582 | dollars as filed | |
| BIOAGE LABS INC COM | 09077V100 | Stock | 1,748,000 | $30,572,520 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 750,000 | $29,790,000 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 1,450,000 | $29,188,500 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 490,000 | $28,493,500 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 530,000 | $27,941,600 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 3,166,600 | $26,821,102 | dollars as filed | |
| PALISADE BIO INC | 696389402 | COMMON STOCK | 10,276,317 | $17,983,555 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 1,485,000 | $17,716,050 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 270,000 | $17,263,800 | dollars as filed | |
| AKTIS ONCOLOGY INC | 01021M104 | COMMON STOCK | 960,847 | $17,189,553 | dollars as filed | |
| CONTEXT THERAPEUTICS INC | 21077P108 | COM | 5,250,000 | $13,755,000 | dollars as filed | |
| PRECISION BIOSCIENCES INC | 74019P207 | COM NEW | 2,236,732 | $12,302,026 | dollars as filed | |
| DBV TECHNOLOGIES S A | 23306J309 | SPONSORED ADS | 574,200 | $11,995,038 | dollars as filed | |
| UNICYCIVE THERAPEUTICS INC | 90466Y202 | COMMON STOCK | 1,000,000 | $6,580,000 | dollars as filed | |
| BRIDGEBIO ONCOLOGY THERAPEUT | 107924102 | COM NEW | 719,000 | $6,435,050 | dollars as filed | |
| LEXEO THERAPEUTICS INC | 52886X107 | COMMON STOCK | 1,100,000 | $6,314,000 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 165,000 | $4,661,250 | dollars as filed | |
| PERSPECTIVE THERAPEUTICS INC | 46489V302 | COMMON STOCK | 791,555 | $3,300,784 | dollars as filed | |
| EVOMMUNE INC | 30054Y107 | COMMON STOCK | 143,472 | $3,298,421 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 7,750,000 | $2,545,875 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001839435-26-000003 | this filing | 2026-05-15 | acceptance time not in the bulk data set |